Latigo Biotherapeutics, Inc.

424B4 priced

Price $18.00 · 19,200,000 shares · Gross proceeds $345,600,000

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Range $16.00 to $18.00 · 16,000,000 shares

Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics, with two product candidates (LTG-001, LTG-321) in clinical development and others in preclinical stages. The company reported significant net losses of $61.2M (2024) and $109.2M (2025), with an accumulated deficit of $266.1M as of March 2026. Financials show increasing operating expenses and ongoing reliance on external capital to fund operations, with current cash reserves of $42.2M projected to last through mid-2028. The filing emphasizes risks related to clinical development, regulatory approval, and financial sustainability.

S-1/A amended

Price $16.00 · Range $16.00 to $18.00 · 16,000,000 shares

Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics, with product candidates in various stages of clinical and preclinical development. The company has incurred significant losses since inception, with net losses of $61.2 million in 2024 and $109.2 million in 2025, and an accumulated deficit of $266.1 million as of March 2026. The current S-1/A filing reflects updated financial projections, including pro forma adjustments for the IPO, with expected cash runway extending into mid-2028. The company emphasizes its need for additional capital to advance clinical trials, secure regulatory approvals, and commercialize its product candidates, while highlighting risks related to clinical development, regulatory hurdles, and financial sustainability.

S-1 filed

Latigo Biotherapeutics, Inc. is conducting an IPO with an assumed initial public offering price of $ per share, reflecting significant financial challenges and capital needs. The offering includes conversions of convertible preferred stock and notes, a reverse stock split, and shares reserved under the 2026 Employee Stock Purchase Plan (ESPP). The company reported net losses of $61.2M (2024) and $109.2M (2025), with an accumulated deficit of $266.1M as of March 2026, highlighting its reliance on future funding to advance clinical-stage therapies.

DRS/A amended

DRS/A amended

DRS filed